The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection
Drug: Linagliptin
5 mg Linagliptin administered by mouth once daily
Other Name: Tradjenta
Drug: Insulin regimen
Standard of care insulin regimen as per hospital protocol
Inclusion Criteria:
- Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines
- Age ≥ 18
- Confirmed COVID-19
- Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore
throat, myalgia, nasal congestion, diarrhea
- Moderate COVID-19 is defined as > 2 of the following in non-intubated patients: any
symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with
bilateral ground glass opacities or bilateral consolidations, SpO2 <90% up to 5L Nasal
Cannula (NC)
- No additional signs or symptoms of severe COVID-19.
Exclusion Criteria:
- Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines
- History of Diabetic Ketoacidosis (DKA)
- History of acute pancreatitis
- Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) < 30
ml/min/1.73 m2
Exclusion Criteria:
T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis;
Chronic or Acute Renal Failure with eGFR < 30 ml/min/1.73 m2
University of Miami
Miami, Florida, United States
Gianluca Iacobellis, MD PhD, Principal Investigator
University of Miami